皮调节素
癌症
危险系数
基因表达
生物
病态的
生存分析
肿瘤科
临床意义
信使核糖核酸
内科学
置信区间
表皮生长因子受体
医学
癌症研究
基因
安非雷古林
遗传学
作者
HIDEAKI SUEMATSU,ITARU HASHIMOTO,YUKIHIKO HIROSHIMA,HAYATO WATANABE,KAZUKI KANO,KOSUKE TAKAHASHI,TORU AOYAMA,TAKANOBU YAMADA,HIROSHI TAMAGAWA,TAKASHI OGATA,NORIO YUKAWA,YASUSHI RINO,MUNETAKA MASUDA,YOHEI MIYAGI,TAKASHI OSHIMA
标识
DOI:10.21873/anticanres.15880
摘要
Epiregulin (EREG) is a ligand of the epidermal growth factor receptor (EGFR) and promotes tumour progression mainly by stimulating the EGF pathway. We investigated the clinical significance of EREG mRNA expression in cancer tissues from patients with gastric cancer (GC) in pathological (p) Stage II/III who have undergone curative surgery.Expression of EREG mRNA was measured in cancer tissues obtained from 253 patients with pStage II/III GC who underwent curative surgery. Patients were divided into groups based on high or low expression of EREG mRNA. We examined the relationship between EREG mRNA expression levels and clinicopathological features and survival.Clinicopathological features did not vary between the high and low EREG mRNA expression groups. Overall survival was significantly lower in the high-expression group compared to that in the low-expression group (5-year survival probability: 55.0% vs. 73.0%; p=0.005). Multivariate analysis showed EREG mRNA expression to be an independent predictor of poor survival (hazard ratio=1.794; 95% confidence interval=1.186-2.712; p=0.006).Expression of EREG mRNA in cancer tissue from patients with pStage II/III GC may be a useful prognostic marker after curative surgery.
科研通智能强力驱动
Strongly Powered by AbleSci AI